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Abstract (250 words) 
Rationale: The treatment of obesity is an increasing global health priority yet few effective 
drug treatments are currently available. The discovery of novel anti-obesity therapies could 
be assisted by the validation of experimental (translational) medicine models in healthy 
volunteers that assess efficacy and safety at an early stage of drug development. Objectives: 
To examine the effects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) 
in an experimental medicine model assessing both appetite and mood. Methods: Using a 
between-subjects double blind placebo controlled design, 24 male and 24 female participants 
were randomly assigned to either placebo, 15mg or 30mg mCPP treatment groups. Lunch 
was eaten from a Universal Eating Monitor (UEM) that measured eating rate and participants 
completed the P1vital® Oxford Emotional Test Battery (ETB) and a series of appetite and 
mood ratings.  Results: mCPP reduced appetite, and in females, enhanced measures of 
satiation. The drug also enhanced memory for emotional material in the word recall and 
recognition memory tasks of the ETB. Conclusions: The results provide new insight into the 
effects of mCPP on appetite, satiety and memory in humans.  In addition, our data provide an 
illustration of the value of measuring changes in appetite and mood in healthy volunteers to 
determine the potential efficacy and safety of novel anti-obesity drugs.  
 
Keywords: experimental medicine, anti-obesity drugs, mCPP, 5-HT2C, ETB, UEM, appetite, 
food intake, satiation quotient, emotional processing, memory.  
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Obesity is an increasing major global health concern and at its annual meeting on 18 June 
2103 the American Medical Association recognised obesity as a disease with multiple 
pathophysiological aspects requiring a range of interventions to advance treatment and 
prevention (AMA 2013). It is a condition of excessive fat accumulation that is associated 
with an increased risk of developing type II diabetes, coronary heart disease, hypertension 
and some cancers (Finucane, et al. 2011). Data from the World Health Organization indicate 
that more than 1 in 10 of the world’s adult population was obese in 2008 (WHO 2012) and 
rates of obesity are predicted to rise over the next decade. It is estimated that by 2020 seven 
of ten British people will be overweight or obese (Sassi 2010). The prevention and treatment 
of obesity is therefore a worldwide healthcare priority.  
 
An effective means to help weight loss, as part of a comprehensive programme, is to 
prescribe drug treatments designed to reduce appetite. At present however, pharmacotherapy 
options for obesity are limited and there have been concerns over the long term efficacy and 
safety of anti-obesity drugs (Li and Cheung 2009). In Europe, there are no centrally acting 
drugs on the market and treatment is limited to the lipase inhibitor, Orlistat (Xenical®, Alli®), 
which works by preventing the breakdown and absorption of fat in the intestinal system 
(Davidson et al. 1999). The Food and Drug Administration (FDA) in the United States has 
recently approved the introduction of two new anti-obesity drug treatments, the 5HT2C 
receptor agonist Lorcaserin (Belviq®) and a combination therapy of phentermine and 
topiramate (Qsymia®). However, the weight loss induced by Lorcaserin is relatively modest 
and while Qsymia is more efficacious than Lorcaserin as a weight loss agent it is associated 
with unpleasant side effects (Heal et al. 2012) and has recently been rejected by the European 
Medicines Agency (EMA) due to concerns about cardiovascular and CNS side effects. 
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Therefore, there is a continued need for the development of new drugs that have the potential 
to deliver greater weight-loss than existing compounds and have an acceptable safety profile.  
 
A barrier to successful development of new drug therapies for obesity is that the costs are 
high and the chance of a novel compound in Phase 1 trials reaching the market is very low 
largely due to failure in late scale clinical trials or during the regulatory approval process 
(Kola and Landis 2004). The cannabinoid CB1 receptor antagonist rimonabant (Acomplia
®) 
was approved by the EMA and marketed for a period in Europe but was refused marketing 
authorization by the FDA due to concerns regarding adverse psychiatric side effects. 
Consequently, marketing authorization for rimonabant in Europe was withdrawn (Butler and 
Korbonits 2009). It is increasingly recognised by the pharmaceutical industry that the 
introduction of Experimental (Translational) Medicine models at the interface between Phase 
1 and Phase 2 clinical trials provides a more effective approach to assessing drug efficacy and 
safety before large scale trials are undertaken (Dawson et al. 2011). Initial efficacy testing of 
novel compounds can also be conducted in healthy volunteers to assess safety issues that 
might pose risks for vulnerable patient populations (Dourish et al. 2008). For example, a 
number of previously marketed drugs for obesity were withdrawn due to cardiovascular 
safety issues, which are a particular concern in obese patients who may have hypertension 
(see below). 
 
Drugs that induce weight loss by enhancing satiety exert effects on energy intake after acute 
dosing in volunteers (Dourish et al. 2008; Halford et al. 2010). For example, the 
noradrenaline and serotonin re-uptake inhibitor sibutramine, which was previously marketed 
as an anti-obesity agent but withdrawn due to increased prevalence of cardiovascular 
problems (Sayburn 2010), has been reported to decrease food in short term studies (Halford 
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et al. 2010). Thus, it is possible to evaluate the potential efficacy of anti-obesity drugs at an 
early stage of clinical development by investigating the acute effects of drug administration 
on food intake. Furthermore, the acute effects of sibutramine on food intake have been 
reported to be mediated by decreases in eating rate, suggesting that analysis of the 
microstructure of eating (Kissileff et al. 1980; Yeomans 1996; Halford et al. 2010) provides 
an experimental marker of anti-obesity drug efficacy.  
 
There is also evidence that drug induced effects on emotional processing that are predictive 
of changes in mood associated with depression can be detected after acute or 7 day dosing in 
healthy volunteers (Harmer et al. 2004; Miskowiak et al. 2007; Browning et al. 2007). 
Furthermore, recent studies have demonstrated increased negative emotional bias following 
administration of the CB1 receptor antagonist rimonabant that are consistent with the 
increased incidence of depression observed in obese patients treated with the drug (Horder et 
al. 2009; Horder et al. 2010).  
 
Our aim in the present study was to validate an experimental medicine model for assessing 
the efficacy and safety of potential anti-obesity therapies in healthy volunteers. The model 
combines assessment of eating microstructural variables using the Sussex Ingestion Pattern 
Monitor (Yeomans 1996) alongside measures of emotional processing using the P1vital® 
Oxford Emotional Test Battery (ETB) (Harmer et al. 2004, 2009; Murphy et al. 2008). We 
examined the effect of a compound that has been reported to alter food intake and mood-
related behaviour in rodents, the preferential 5-HT2C receptor agonist meta-
chlorophenylpiperazine (mCPP) (Kitchener and Dourish 1994; Kennett et al. 1994; Hewitt et 
al. 2002). The anorectic effects of mCPP in humans have been reported previously (Walsh et 
al. 1994; Sargent et al. 1997) but detailed effects of this compound on appetite have yet to be 
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investigated. Similarly, it has been known for some time that mCPP can increase anxiety in 
healthy volunteers and in patients with panic disorder (Charney et al. 1987; Kahn et al. 1990) 
but this is the first detailed assessment of the effects of mCPP in a battery of psychological 
tasks. We predicted that mCPP would decrease food intake and enhance microstructural 
measures of satiety as well as increase anxiety and negative mood measured by the ETB.  
 
Methods & Materials 
Participants 
48 healthy student volunteers (24 males and 24 four females) were recruited from the 
University of Birmingham; mean age 20.92 years (range 18-27), mean BMI 22.38 (range 
18.93-26.30). The study was advertised via posters, as an ‘Appetite and Mood Study 
examining the effects of mCPP’. Participants received £80 compensation upon completion. 
Informed consent was obtained, ethical approval was provided by South Birmingham 
Research Ethics Committee (National Research Ethics Service), and the study was conducted 
in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. 
Participants were screened to exclude the following: under 18 or over 65 years old, Body 
Mass Index (BMI) under 18.5 or over 27.5, English not first language as determined by the 
National Adult Reading Test (NART – Nelson 1982), taking psychotropic medication, past or 
current Axis 1 disorder as determined by the Structured Clinical Interview for DSM-IV Axis 
I Disorders (SCID – Spitzer et al. 2004), pregnant or breast feeding, smoker, dyslexic, food 
allergies, vegan or vegetarian, diabetic, not using contraception (females), cognitive restraint 
score higher than 10 as measured by the Three Factor Eating Questionnaire (TFEQ - 
Stunkard and Messick 1985), and low rated pleasantness (<65) or low consumption of the test 
meal (<150g) on the food screening day. Females were not tested during their premenstrual 
week. 
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Design 
The study used a parallel group, double-blind, placebo controlled design. A 30mg oral dose 
of mCPP was selected, as similar doses have been shown to reduce appetite, and, in some 
cases, induce nausea and anxiety (Sargent et al. 1997; Walsh et al. 1994; Cowen et al. 1995; 
Kahn et al. 1990). Therefore, a 15mg dose was also used, as this dose is not associated with 
nausea, but may still affect appetite (Smith et al. 1994). The study had three conditions: 
placebo, 15mg mCPP, and 30mg mCPP (mCPP was supplied by the Guy’s and St Thomas’ 
NHS Foundation Trust Pharmacy Manufacturing Unit - GSTFT). Each group comprised 16 
participants (8 males and 8 females), and both medication and placebo were prepared in 
identical capsules to maintain blinding.  
 
Sussex Ingestion Pattern Monitor (SIPM) 
Test meals were served on a SIPM. This consisted of a balance (Sartorius Model CP4201; 
Sartorius Ltd, Epsom, UK; 0.1g accuracy) placed underneath, but protruding through, the 
surface of a table. A placemat on the table was used to hide the balance from the participants 
view. The balance was connected to a laptop computer. Using the procedure described by 
Yeomans (1996; 2000), plates containing 200g of pasta were placed on the mat and the 
amount of food eaten every 2 seconds was recorded covertly. The SIPM software (version 
2.0.8) was configured to interrupt participants each time they had eaten 50g of the meal and 
ask them to complete VAS ratings of hunger, fullness and pleasantness of the pasta. After 
150g had been consumed, participants were interrupted and the plate was replaced with a 
fresh 200g plate of pasta. Participants were asked to eat in this manner until they felt 
‘comfortably full’. The test meal consisted of pasta shells in a tomato and herb sauce (both 
Sainsbury’s brand), served at 55-60oC (233 kcal per 200g serving).  
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P1vital® Oxford Emotional Test Battery (ETB) 
The ETB is a computerised battery that comprises five validated cognitive tests (see 
http://www.p1vital.com/Oxford%20Emotional%20Test%20Battery/index.html) which have 
been used in previous acute drug studies of emotional behaviour (e.g. Harmer et al. 2004; 
Murphy et al. 2008).  
Facial expression recognition task (FERT): faces with one of six emotional expressions 
(happiness, fear, anger, disgust, sadness and surprise) or a neutral expression were displayed. 
The pictures (from Ekman and Friesen 1976) were morphed from neutral to 100% 
expressions (Young et al. 1997) in 10% stages, producing 10 intensities for each emotion. 
Each intensity was presented four times for each emotion, along with 10 presentations of 
neutral expressions, yielding 250 stimuli. These were presented for 500ms, followed by a 
blank screen. Participants classified each expression as quickly and accurately as possible, 
using the button box provided. Accuracy, response bias (bias towards one emotion over 
another) and target sensitivity (ease in detecting the target stimulus from other stimuli) were 
calculated. 
Faces dot probe task (FDOT): pairs of photographs (from Matsumoto and Ekman 1988) were 
presented comprising either: one emotional (either happy or fearful) and one neutral facial 
expression, or two neutral expressions. Faces appeared above or below a central fixation 
point. For unmasked trials the pair was displayed for 100ms, whereas for masked trials, the 
pair was displayed for 16ms, then replaced with a mask for 84ms; for both trials, the images 
were then replaced with a probe, located in the position of one of the faces (or masks). The 
probe consisted of a pair of dots, in either a vertical (:) or horizontal (··) orientation. 
Participants indicated the orientation as quickly and accurately as possible using the 
corresponding buttons on the button box. There were192 trials: 32 happy + neutral; 32 fear + 
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neutral; 32 neutral + neutral for both masked and unmasked trials. Vigilance (sustained 
attention) scores were calculated. 
Emotional categorisation task (ECAT): sixty positive and negative self-referent personality 
descriptors (e.g. “cheerful” vs. “hostile”) (Anderson 1968), were displayed for 500ms. Words 
were matched for meaningfulness, length and frequency of occurrence. Participants indicated 
using the button box whether they would like or dislike to be described as such, as quickly 
and accurately as possible. Accuracy and reaction times were measured. 
Emotional recall task (EREC): participants were asked to recall as many words as they could 
remember from the ECAT, within a four minute period. This task was partly computerised; 
instructions given via computer, but words written down using pen and paper. The number of 
correct words recalled and their valence was measured. 
Emotional recognition memory task (EMEM): participants were presented with a series of 
words on a computer screen, containing the 60 personality descriptors from the ECAT, along 
with 60 matching novel distracter words. Participants were instructed to use the button box, 
pressing ‘yes’ or ‘no’ to indicate whether the word had been presented during the ECAT. 
Accuracy, response bias and target sensitivity were calculated. 
 
Biological samples 
Salivary cortisol: saliva was collected using salivettes (SARSTEDT). Participants abstained 
from drinking water for 30 minutes prior to giving the sample, and then chewed on a 
synthetic cotton wool swab for 60 seconds, before the sample was taken to be centrifuged for 
2 minutes at 1000g, and then frozen at -80oC until analysed. Salivary cortisol was measured 
by liquid chromatography-mass spectrometry (LC-MS/MS) by the Clinical Laboratory 
Services, University Hospitals Birmingham NHS Foundation Trust. A Waters Aquity UPLC 
system was used for chromatography connected to a Waters Premier XE tandem mass 
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spectrometer with an electrospray ion source. Intra-assay coefficients of variation (CVs) were 
<5.9% and inter-assay CVs <9.8% between 3 and 47 nmol/L. The lower limit of 
quantification (defined as the lowest concentration at which the CV is <20%) was 1.6 
nmol/L.    
 
Procedure 
The experimental procedure is summarised in Figure 1. 
Screening Days: participants underwent an initial screening at the School of Psychology 
(University of Birmingham) for exclusions, and completed the Eysenck Personality 
Questionnaire (EPQ - Eysenck and Eysenck 1975) to determine baseline personality traits. 
They returned approximately one week later for a trial run with the test meal served; those 
who liked and ate a sufficient amount of the pasta proceeded to the test day. 
Test Day: participants arrived at the Welcome Trust Clinical Research Facility (University 
Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital) at 8.00, 9.00 or 
10.00am. It was ensured that participants had eaten their normal breakfast two hours earlier 
by asking them to complete a breakfast questionnaire detailing their food intake that morning. 
Participants then completed a physical health check with a physician (including blood 
pressure and an electrocardiogram (ECG), were breathalysed and completed a pregnancy test 
if female. Only individuals who passed the health and alcohol check, and females who were 
not pregnant, were allowed to continue. Participants also completed baseline VAS for mood 
and appetite that comprised: ‘alertness’, ‘disgust’, ‘drowsiness’, ‘light-headed’, ‘anxiety’, 
‘happiness’, ‘nausea’, ‘sadness’, ‘withdrawn’, ‘faint’, ‘hungry’, ‘full’, ‘desire to eat’ and 
‘thirst’. 1.5 hours after the start of the session, participants completed a pre-dose Beck 
Depression Inventory (BDI – Beck et al. 1961), Befindlichskeit scale of mood and energy 
(BFS - von Zerssen et al. 1974), and Positive and Negative Affective Schedule (PANAS – 
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Watson et al. 1988), as measures of subjective mood and energy. They also completed a State 
Trait Anxiety Inventory (STAI - Spielberger 1983) as an index of their anxiety, and another 
set of VAS (as described above). After 2.5 hours, further VAS were completed along and a 
saliva sample was taken, after which participants were administered the test dose (either 
placebo, 15mg mCPP or 30mg mCPP). VAS were completed every 30 minutes. 4.5 hours 
after the start of the session, participants were given ad libitum access to the test meal on the 
SIPM, and completed the computerised VAS during the meal. Following the meal, 
participants completed post-dose: BDI, BFS, PANAS, STAI and VAS. A saliva sample was 
taken an hour after lunch and participants then completed the ETB (which took 
approximately 90 minutes). A final set of VAS and a saliva sample were taken at the end of 
the session, along with a single blood sample. Participants were fully debriefed and 
questioned to determine if they were aware of the hidden balance or the aims of the study 
(See Figure 1 for a summary of the procedure). 
 
Data Analysis 
General: one participant did not complete testing, and their data was removed from all 
analyses (female 30mg mCPP group). For statistical analyses, effects and interactions with 
condition were determined with analysis of variance (ANOVA) and followed up with 
planned comparisons; interactions with condition were also analysed if approaching statistical 
significance. Dunnett’s correction was used for all t-tests, and violations of sphericity were 
addressed using the Greenhouse-Geisser correction.  
VAS: To establish a factor structure for the VAS, a principal components analysis (PCA) was 
run with varimax rotation. Analysis of the 14 items provided 5 factors with eigenvalues > 1, 
accounting for 70.81% of the variance. Items that loaded > 0.5 onto a factor were included, 
resulting in four factors of 3 or more items: appetite (hunger, fullness and desire to eat), 
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physical effects (lightheaded, nausea and faint), negative effects (disgust, anxiety, sadness, 
withdrawn and thirst) and arousal (alertness, drowsiness and happiness). Scores for each of 
the factors were calculated by summing the scores for all items in that factor, and then 
dividing by the number of items (items with a negative scale, were inverted to match the 
other items).  
SIPM: For the SIPM, microstructural data for 12 participants were lost due to technical issues 
with the balance, so data for 35 participants were analysed. For total intake and correlational 
analysis, an estimate of intake was used (e.g. where intake data were missing for a plate, it 
was assumed that if the plate was finished, the individual had eaten approximately 150g).  
 
Results 
Participant Characteristics 
The groups did not differ in age, BMI or EPQ scores (all p > 0.05). There was a main effect 
of gender for the NART, with males scoring higher scores than females (F (1 41) = 5.12; p < 
0.05) and for the TFEQ factor cognitive restraint, with females showing higher restraint than 
males (F (1 41) = 4.19; p < 0.05), but there were no other main effects or interactions at 
baseline (Table 1).  
 
Salivary Cortisol 
Salivary cortisol was analysed by gender, condition, and time (baseline measure: t0; time 
after dosing: t60, t120, t180, t300). There was a main effect of time (F (4 164) = 7.07; p < 
0.001), condition (F (2 41) = 12.32; p < 0.001), an interaction between condition and time (F 
(8 164) = 2.49; p < 0.05), and an interaction between time and gender which was not further 
analysed (F (4 164) = 3.42; p < 0.05). Post hoc analysis showed there were main effects of 
condition for t60 (F (2 44) = 7.41; p < 0.01), t120 (F (2 44) = 8.37; p < 0.01) and t300 (F (2 
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44) = 6.16; p < 0.01). Cortisol was significantly higher in the 15mg mCPP condition 
compared to placebo at t60 (t (30) -2.43; p < 0.05); while cortisol was higher in the 30mg 
mCPP condition compared to placebo for t60 (t (29) -4.18; p < 0.01), t120 (t (29) -3.86; p < 
0.01) and t300 (t (29) -3.36; p < 0.01) (Figure 2). There was no interaction between gender 
and condition (F (2 41) = 0.32; p > 0.05), or gender, condition and time (F (8 164) = 3.29; p > 
0.05), indicating no differential cortisol response for males vs. females to mCPP. 
 
Subjective State Questionnaires   
Data were analysed by gender, condition, and time (pre vs. post-dosing). There were no main 
effects or interactions for the BDI, STAI Trait & State, or PANAS negative scores (all p > 
0.05). There was, however, a main effect of time for PANAS Positive scores, with a small 
decrease in positive affect over the day (from 30.43 to 28.11; F (1 41) = 9.64; p < 0.01). For 
the BFS, there a significant interaction between time and condition (F (1 42) = 4.363; p < 
0.05), whereby the placebo group BFS score decreased over time (t (15) 2.18; p = 0.05). 
 
Visual Analogue Scales 
Pre-dosing VAS scores were averaged for a pre-dose baseline. Each factor (negative effects, 
arousal, appetite, and physical effects) was analysed separately, by condition and gender, 
showing no main effects or interactions (all p > 0.05). Post-dosing factors were then analysed 
by gender, condition and time (post-dosing in minutes: t30, t60, t90, t120, t150, t210).   
 
Negative effects & Arousal: There were no main effects or interactions for negative effects 
(all p > 0.05). For arousal, there were no main effects (all p > 0.05), but a significant two way 
interaction between time and condition (F (5 107) = 2.37; p < 0.05); follow up tests were not 
statistically significant (all p > 0.05), though there was a near significant effect of condition 
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for t210 (F (2 44) = 2.67; p = 0.08), with mean arousal scores of; 64.69 for placebo, 75.79 for 
15mg mCPP and 75.22 for 30mg mCPP. 
 
Physical Effects: There was a main effect of time (F (3 117) = 160.94; p < 0.01) and 
condition (F (2 41) = 5.97; p < 0.01 – Figure 3), and a significant two way interaction (F (6 
117) = 3.25; p < 0.01). Main effects of condition were observed for: t60 (F (2 44) = 6.62; p < 
0.01), t90 (F (2 44) = 7.83; p < 0.01) and t120 (F (2 44) = 4.69; p < 0.05), with physical 
effects rated significantly higher in the 30mg mCPP group than placebo (all p < 0.05 – Figure 
3).  
  
Appetite: There was a main effect of time (F (3 115) = 237.00; p < 0.001) and condition (F (2 
41) = 3.78; p < 0.05 – Figure 3) but no significant interaction. For the effect of time, all 
comparisons were significantly different (all p < 0.05), and for condition, appetite was 
significantly lower in the 30mg mCPP group than placebo (t (29) 2.30; p < 0.05 - Figure 3).  
 
Meal measures 
Test meal intake: There was a main effect of gender only, with males eating more than 
females (F (1 29) = 11.32; p < 0.01). There was no effect of condition nor any interaction 
(Table 1). 
 
Meal Intake quartiles: amount eaten was analysed by quartile, gender, and condition, 
showing a main effect of quartile (F (3 87) = 8.18; p < 0.01), gender (F (1 29) = 11.32; p < 
0.01) and a two way interaction between quartile and condition (F (6 87) = 2.56; p < 0.05) 
although follow up tests were not significant. Males ate more than females (174.09 grams vs. 
106.57 grams). Males had a faster eating rate than females (105.72g/min vs. 67.23g/min; F (1 
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29) = 13.51; p < 0.01) and ate larger mouthfuls than females (12.06 grams vs. 7.76 grams; F 
(1 29) = 6.56; p < 0.05). 
 
Computerised VAS: Hunger decreased across quartiles (F (2 50) = 150.46; p < 0.001), and 
males were more hungry than females (47mm vs. 38mm, respectively; (F (1 29) = 3.81; p = 
0.06). (all p < 0.001). Similarly, fullness increased across quartiles (F (2 47) = 176.78; p < 
0.001), and males were less full than females; (59mm vs. 51mm, respectively; (F (1 29) = 
4.46; p < 0.05)). For pleasantness, there was a main effect of quartile only (F (2 45) = 31.65; 
p < 0.001), with rated pleasantness decreasing across quartiles (all p < 0.05).  
 
Satiation Quotient 
The satiety quotient (Green et al. 1997 (pre-meal hunger – post meal hunger) / calories 
consumed) provides a measure of how satiating a given amount of calories is at time points 
after an eating episode has finished. Adapting this, we calculated a satiation quotient (SQ) per 
quartile, a measure reflecting the satiating capacity of a food as it is eaten (quartile initial 
hunger – quartile ending hunger rating) / calories consumed during quartile). There was a 
main effect of quartile (F (3 87) = 11.62; p < 0.001) and gender (F (1 29) = 7.11; p < 0.05), a 
two way interaction between gender and condition (F (2 29) = 8.61; p < 0.01), and a three 
way interaction between quartile, gender and condition (F (6 87) = 2.50; p < 0.05). For males 
there was an effect of quartile (F (3 36) = 6.87; p < 0.01) and condition (F (2 12) = 4.30; p < 
0.05). SQs were significantly lower in the 30mg mCPP group compared to placebo (t (8) = 
2.72; p < 0.05) and  there was a significant increase in SQ from quartile 2 to 3 (t (14) -2.86; p 
< 0.05). For females there was a main effect of quartile (F (3 51) = 6.53; p < 0.01), condition 
(F (2 17) = 4.84; p < 0.05) and an interaction between quartile and condition (F (6 51) = 2.58; 
p < 0.05). Breaking down the interaction by quartile; for quartile 1, SQ was significantly 
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higher for 30mg mCPP than placebo (t (11) = -2.44; p < 0.05); and for quartile 2, SQ was 
significantly higher for both 15mg mCPP and 30mg mCPP, compared to placebo (t (13) = -
3.07; p < 0.01; t (11) = -2.69; p < 0.05) (Table 2). 
Correlations  
To investigate the relationship between appetite, physical symptoms (both measured prior to 
lunch) and total food intake, correlations were performed on the three measures. A positive 
correlation was identified between appetite and intake (r (47) = 0.32, p < 0.05), but there was 
no association between physical symptoms and intake, or between physical symptoms and 
appetite (r (47) = -0.05, p > 0.05; (r (47) = -0.15, p < 0.05).  
 
Emotional Test Battery (ETB) Data  
Facial expression recognition task (FERT) & Faces dot probe task (FDOT): There were 
main effects of emotion (F (3 140) = 35.46; p < 0.001; F (6 246) = 130.28; p < 0.001) but no 
other significant effects or interactions for target sensitivity and response bias (all p > 0.05). 
There were no significant main effects or interactions for vigilance scores (all p > 0.05). 
Emotional categorisation task (ECAT): Accuracy data showed a main effect of gender only, 
with females showing greater accuracy than males (96.70% vs. 89.34%, respectively; F (1 
40) 4.36; p < 0.05). Reaction time showed a main effect of valence only, with longer reaction 
times to negative vs. positive stimuli (887.36ms vs. 825.36ms, respectively; F (1 40) 19.47; p 
< 0.001).   
 
Emotional recall task (EREC): More positive than negative words were recalled (5.8 vs. 3.8 
words; F (1 41) = 38.97; p < 0.001). There was also a main effect of condition (F (2 41) = 
4.77; p < 0.05) with more words correctly recalled in the 15mg mCPP and the 30mg mCPP 
groups than placebo (5.1 & 5.6 vs. 3.6, respectively) (both p < 0.05 - Figure 4).  
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Emotional recognition memory task (EMEM): Target sensitivity showed a main effect of 
condition only (F (1 41) = 5.87; p < 0.01), whereby target sensitivity was significantly higher 
in the 30mg mCPP group than placebo (t (23) -4.31; p < 0.001 – Figure 4). 
Discussion 
The 5-HT2C receptor agonist mCPP at doses of 15mg and 30mg decreased appetite ratings of 
both male and female participants, and enhanced within-meal satiation quotients (SQs) of 
female participants in a dose related manner but had no significant effect on food intake. 
mCPP also dose-dependently increased ratings of negative physical effects (in particular 
nausea) but had no effects on ratings of negative mood or cognitive measures of anxiety and 
depression as assessed by the ETB. Interestingly, we provide the first evidence that mCPP 
may enhance memory for emotional words independent of their valence.  
 
As expected, mCPP dose-dependently increased salivary cortisol, confirming activation of 5-
HT2C receptors. Peak effects for both doses occurred 60-180 minutes post dosing, which is 
consistent with previous reports (Kahn et al. 1990). In addition, the 30mg dose of the drug, 
but not the 15mg dose, induced negative physical symptoms in participants, a finding which 
also confirms the results of previous studies (Walsh et al. 1994). Taken together, these data 
suggest that mCPP activated 5-HT2C receptors at concentrations sufficient to exert effects on 
eating and emotional behaviour. 
 
Appetite ratings were attenuated by 30mg mCPP, but not by 15mg mCPP, a finding that 
consistent with previous reports (Cowen et al. 1995; Smith et al. 1994). Interestingly, the 
results for the SQ, showed a dose-dependent effect of mCPP, but only in females. Thus, SQs 
were enhanced in the first half of the test meal at both 15mg and 30mg mCPP, with an earlier 
onset of action at the 30mg mCPP dose. mCPP failed to significantly decrease food intake 
 18 
 
compared to placebo suggesting that VAS ratings and the SQ measure derived from SIPM 
microstructural data may be more sensitive to the effects of mCPP (at least in females) on 
eating than measurement of food consumption. The apparent acceleration of satiation by 
mCPP in lean females in the present study is similar to that observed with the 5-HT reuptake 
inhibitor sibutramine in obese females (Halford et al. 2010) and may be part of a common 
mechanism by which 5-HT2C receptor activation reduces food intake.  
 
We observed differences between males and females in eating patterns and the response to 
mCPP. Males ate more than females and at a faster rate. While both males and females had 
reduced appetite ratings after mCPP only females showed enhanced satiety. These differences 
are unlikely to be explained by male/female differences in body weight, drug distribution, or 
metabolism because there were no gender effects observed for mCPP induced increases in 
cortisol. One possibility is that although the males experienced an effect of mCPP on appetite 
they are less sensitive to the drug effects on actual food intake measured in the context of the 
laboratory. Several male participants ate close to (or more than) 1kg of pasta, which suggests 
that they may have been eating larger amounts than usual. It would be informative to assess 
the response of male participants to the effects of mCPP on intake at usual meals taken in the 
home.  
 
It appears unlikely that the effects of 15mg mCPP on appetite and satiety were confounded 
by nausea as this dose did not induce significant physical effects. However, it is possible that 
nausea could have confounded the effects on appetite seen at the 30mg dose of mCPP. This 
does not seem plausible, however, as neither appetite nor food intake correlated with physical 
symptoms. This interpretation is consistent with the results of a previous study in which 
nausea also failed to correlate with food intake or appetite ratings (Walsh et al. 1994). In 
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addition, the pattern of effects for appetite and nausea are distinct, as 30 mCPP attenuated 
appetite earlier, and for a longer duration, than the induction of nausea. 
 
On the basis of previous research (Charney et al. 1987; Kahn et al. 1990), we predicted that 
mCPP might induce anxiety and or depression-like symptoms. The pattern of results from the 
ETB, however, is not consistent with the induction of anxiety or depression-like responses by 
mCPP. Thus, there was no significant effect of mCPP administration on responses to fearful 
or angry facial expressions which are generally indicative of heightened anxiety (Mogg & 
Bradley 2002; Harmer et al. 2003). Nor were there any responses indicative of depression, 
such as the reduced recall of positive stimuli that has been observed after acute treatment 
with the CB1 receptor antagonist rimonabant (Horder et al. 2009). Previous studies that have 
reported anxiogenic effects of mCPP generally administered the drug as an intravenous bolus, 
and so it is possible that effects on anxiety are less evident with the oral route of 
administration used in the present study (Kahn et al. 1990; Silverstone and Cowen 1994; 
Cowen et al. 1995; Anderson et al. 2002). The lack of an mCPP-induced depressogenic or 
anxiogenic effect on the ETB tasks is consistent with the absence of any effects observed on 
the questionnaire based measures of anxiety and mood.   
 
Most interestingly however, mCPP dose dependently enhanced memory for emotional words 
an effect that was independent of valance. Previous studies in rodents suggest that mCPP may 
impair memory function (Khaliq et al. 2012). However, studies in human volunteers have 
linked tryptophan depletion to memory impairment, and citalopram enhancement of 
serotonergic function with facilitation of memory consolidation (Hayward et al. 2005; 
Harmer et al. 2002). The present results are consistent with these findings and suggest that 5-
HT2C receptors may mediate the facilatory effects of citalopram on memory.  
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Previous research has shown that enhancing memory of an eating episode decreases 
subsequent food intake (Higgs and Donohoe 2011). Thus, it is possible that long term use of 
mCPP and other serotonergic drugs could enhance memories of food consumption and reduce 
subsequent food intake (possibly having an additive effect with the acute drug response 
observed in the present study). This theory of drug induced memory enhancement as a 
mechanism to reduce food intake, is supported by findings with the NMDA receptor 
antagonist memantine. Thus, memantine has been reported to enhance memory in animals 
and humans and to enhance satiety in non-human primates (Parsons et al. 2007; Foltin et al. 
2008). This suggests that memory enhancement might play a role in enhanced satiation, and 
could provide a novel target for future weight loss drugs. 
 
In conclusion, the present results provide an informative profile of the preferential 5-HT2C 
agonist mCPP in an acute experimental medicine model that can measure drug effects on 
eating, satiety and mood in humans. For the first time, we show that effects of a low (15mg) 
dose of mCPP on appetite and satiety are detectable using a SIPM to measure drug- induced 
enhancement of within-meal satiation which appears to be a promising marker of an 
efficacious anti-obesity drug. The model can also detect drug induced changes in emotional 
processing. Thus, an enhancement of memory for emotional stimuli by mCPP was observed 
for the first time supporting a role for 5-HT2C receptors in cognition. Further research is 
needed with obese participants to ensure translation of results in this model to relevant 
clinical populations and with other drug classes to identify markers of their potential efficacy 
and safety. 
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Tables & Figures 
 
 
Table 1 Participant characteristics, baseline means, and test meal intake (standard error of the 
mean) 
 
Male Female 
  Placebo 15mg 30mg Placebo 15mg 30mg 
Gender 8 8 8 8 8 7 
Age 20.8 (0.4) 21.9 (0.8) 20.4 (0.5) 22.4 (1.0) 20.4 (0.5) 19.9 (0.7) 
BMI 23.8 (0.7) 22.1 (0.7) 22.8 (0.8) 21.5 (0.7) 22.0 (0.8) 22.4 (0.9) 
NART 114.9 (1.0) 114.6 (1.7) 112.6 (1.6) 112.9 (1.0) 111.9 (1.6) 109.7 (0.9) 
TFEQ CR 4.3 (1.4) 3.6 (1.0) 3.1 (1.0) 6.9 (0.9) 5.5 (1.1) 4.1 (1.2) 
EPQ N 4.0 (0.8) 4.0 (1.0) 4.0 (1.0) 7.9 (1.1) 3.3 (1.3) 4.1 (0.6) 
Test Meal  649.3 (90.1) 778.2 (111.6) 663.8 (107.7) 510.1 (60.2) 442.8 (31.1) 409.2 (66.9) 
Intake (grams) 
      
              
       BMI - Body Mass Index; NART - National Adult Reading Test; TFEQ - Three Factor Eating Questionnaire 
(CR - Cognitive Restraint); EPQ - Eysenck Personality Questionnaire (N - Neuroticism) 
 
Table 2 Mean female satiation quotients by quartile and 
condition (standard error of the mean) 
 
Condition 
Quartile Placebo 15mg 30mg 
1 0.04 (0.04) 0.04 (0.02) 0.20 (0.05)* 
2 0.10 (0.02) 0.21 (0.03)** 0.21 (0.04)* 
3 0.18 (0.05) 0.21 (0.05) 0.46 (0.16) 
4 0.17 (0.04) 0.20 (0.06) 0.09 (0.02) 
        
Compared to placebo: p < 0.05*; p < 0.01** 
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Fig. 1 Flow diagram for Screening Days (initial screening day & trial run of test meal on a separate 
day) followed by an overview of Test Day timings in hours (hrs). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Salivary cortisol levels over time for placebo, 15mg mCPP, and 30mg mCPP. The 15mg group 
showed a significant increase in salivary cortisol compared to the placebo group at t60, and the 30mg 
group showed an increase at t60, t120 and t300. Error bars represent standard error of the mean. *p < 
0.05; **p < 0.01 
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Fig. 3 For appetite (Panel A) there was a main effect of condition (histogram on right panel) where 
appetite was significantly lower in the 30mg group compared to the placebo group, but no significant 
interaction (graph on left panel – post hoc t-tests showing a difference between placebo and 30mg at 
t30 only). Physical effects VAS scores (Panel B) showed a main effect of condition (histogram on 
right panel) and an interaction between condition and time (graph on left panel), where physical 
effects were significantly higher for the 30mg group at t60, t190, and t120, compared to placebo. 
Error bars represent standard error of the mean. *p < 0.05; **p < 0.01 
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Fig. 4 Mean number of words correctly recalled (left panel) and mean target sensitivity (right panel) 
for placebo, 15mg mCPP and 30mg mCPP groups in the emotional recall task. Word recall was 
enhanced in both the 15mg and 30mg groups compared to placebo and target sensitivity was enhanced 
in the 30mg group compared to placebo. Error bars represent standard error of the mean. *p < 0.05; 
***p < 0.001 
